CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,294 enrolled
Drug / intervention
Vancomycin +1 moredrug
Likely dose
Vancomycin (dose not specified in interventions or arms)AI-extracted
Key inclusion· 5
  • ✓Age 18 years or older
  • ✓Initiated on high-risk antibiotic (clindamycin, ampicillin, fluoroquinolone, cephalosporin, or piperacillin/tazobactam) within prior 72 hours with expected duration ≥72 hours
  • ✓Expected antibiotic duration of at most 8 weeks
  • ✓Able to take oral medications
Key exclusion· 8
  • ✕Active or recent CDI within prior 90 days
  • ✕Currently on C. difficile-active antibiotics (metronidazole, oral vancomycin, rifaximin, fidaxomicin, or similar)
  • ✕Current diarrhea
  • ✕Inflammatory bowel disease (Crohn's disease, ulcerative colitis) or other chronic diarrheal illness

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02996487
NCT02996487Phase 4Completed
CompareCT.gov

Screening to Prophylax Against Clostridium Difficile Infection

Corewell Health East·interventional·Posted Dec 19, 2016·Updated Aug 13, 2024

In Brief

A Phase 4 clinical trial evaluating Vancomycin and Placebo for Clostridium Difficile Infection. Completed, enrolled 1,294 participants across 3 sites.

Detailed Summary

The goal of this study is to evaluate whether using vancomycin orally can prevent CDI in patients who are colonized with C. difficile who are admitted to the hospital and need antibiotics for another infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClostridium Difficile Infection
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 19, 2016
Enrollment StartDec 19, 2016
Primary CompletionJun 28, 2023
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 9.5 years ago

Interventions

Vancomycindrug

Placeboother